Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug R&D May Depend On Govt. Funds If Price Disparities Persist – Crawford

Executive Summary

Drug price controls in the international market could lead to a reliance on government funds for pharmaceutical R&D, FDA Acting Commissioner Lester Crawford said

You may also be interested in...

Importation Debate Highlights Need For Lower Rx Prices, McClellan Says

The debate over drug importation highlights the need for reduced drug prices, Centers for Medicare & Medicaid Services Administrator Mark McClellan said Aug. 30

Illinois Reimportation Plan Goes Beyond Canada, Enlists PBM

Illinois will contract with a non-domestic PBM to administer personal drug reimportation from Ireland, the United Kingdom and Canada

Global Price Controls Elimination May Not Affect U.S. Rx Costs – Economist

Eliminating pharmaceutical price controls in foreign countries would result in more innovation, but not necessarily lower prices for U.S. consumers, American Enterprise Institute economist Kevin Hassett said during an International Trade Administration meeting Aug. 3

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts